期刊文献+

美沙拉嗪对溃疡性结肠炎患者血清CRP,IL-10及TNF-α水平的影响 被引量:18

Effect of Mesalazine on Serum Levels of CRP, IL-10 and TNF-α in Patients with Ulcerative Colitis
原文传递
导出
摘要 目的:探讨美沙拉嗪对溃疡性结肠炎患者血清CRP,IL-10及TNF-α水平的影响。方法:收集我院就诊的120例溃疡性结肠炎患者,随机分为实验组和对照组,每组60例。两组给予柳氮磺吡啶肠溶片治疗,实验组患者给予美沙拉嗪肠溶片治疗。观察并比较两组患者治疗前后血清C-反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)及白介素-10(IL-10)水平、临床疗效及安全性。结果:与治疗前相比,治疗后两组患者血清CRP及TNF-α水平均下降,而IL-10水平均升高,差异具有统计学意义(P<0.05);与对照组相比,实验组患者血清CRP及TNF-α水平较低,而IL-10水平较高,差异具有统计学意义(P<0.05);与对照组相比,实验组患者临床治疗有效率较高,不良反应发生率较低,差异具有统计学意义(P<0.05)。结论:美沙拉嗪能够抑制溃疡性结肠炎患者的炎症反应水平,降低CRP、TNF-α水平,升高IL-10水平,临床疗效较好,且用药安全。 Objective: To investigate the effects of mesalazine on serum levels of CRF, IL-10 and TNF-α in of patients with ulcerative colitis. Methods: 120 patients with ulcerative colitis were randomly divided into the experimental group and the control group, with 60 cases in each group. The patients in the control group were treated with sulfasalazine enteric-coated tablets, while the patients in the experimental group were treated with mesalazine enteric-coated tablets. Then serum levels of C- reactive protein (CRP), tumor necrosis factor alpha (TNF-α) and interleukin-10 (IL-10), and clinical efficiency and safety in the two groups were observed and compared before and after the treatment. Results: Compared with before treatment, the serum levels of CRP and TNF-α decreased, while the levels ofIL-10 increased in the two groups after treatment, and the differences were statistically significant (P〈0.05); Compared with the control group, the serum levels of CRP and TNF-α were lower, and the IL-10 was higher in experimental group, and the differences were statistically significant (P〈0.05); Compared with the control group, the clinical effective rate in the experimental group were higher, while the incidence of adverse reactions was lower, and the differences were statistically significant (P〈0.05). Conclusion: Mesalazine can reduce the serum levels of IL-10, CRP and TNF-α in patients with ulcerative colitis, which is effective and safety for clinical treatment.
出处 《现代生物医学进展》 CAS 2017年第14期2693-2696,共4页 Progress in Modern Biomedicine
基金 辽宁省科技攻关计划项目(2011225038)
关键词 美沙拉嗪 溃疡性结肠炎 CRP IL-10 TNF-Α Mesalazine Ulcerative colitis C-reactive protein Interleukin-10 Tumor necrosis factor alpha
  • 相关文献

参考文献2

二级参考文献24

  • 1Shigeo Koido,Toshifumi Ohkusa,Kazuki Takakura,Shunichi Odahara,Shintaro Tsukinaga,Toyokazu Yukawa,Jimi Mitobe,Mikio Kajihara,Kan Uchiyama,Hiroshi Arakawa,Hisao Tajiri.Clinical significance of serum procalcitonin in patients with ulcerative colitis[J].World Journal of Gastroenterology,2013,19(45):8335-8341. 被引量:15
  • 2Maria Papp,Gary L Norman,Istvan Altorjay,Peter Laszlo Lakatos.Utility of serological markers in inflammatory bowel diseases: Gadget or magic?[J].World Journal of Gastroenterology,2007,13(14):2028-2036. 被引量:24
  • 3Ingrid Ordás,Lars Eckmann,Mark Talamini,Daniel C Baumgart,William J Sandborn.Ulcerative colitis[J]. The Lancet . 2012 (9853)
  • 4Bhavya Voleti,David J. Hammond,Avinash Thirumalai,Alok Agrawal.Oct-1 acts as a transcriptional repressor on the C-reactive protein promoter[J]. Molecular Immunology . 2012 (3-4)
  • 5Heba N. Iskandar,Matthew A. Ciorba.Biomarkers in inflammatory bowel disease: current practices and recent advances[J]. Translational Research . 2012 (4)
  • 6Nitin K. Gupta,Ameet I. Thaker,Navya Kanuri,Terrence E. Riehl,Christopher W. Rowley,William F. Stenson,Matthew A. Ciorba.Serum analysis of tryptophan catabolism pathway: Correlation with Crohn’s disease activity[J]. Inflamm Bowel Dis . 2011 (7)
  • 7Shih‐Kuang S.Hong,Brad E.Maltz,Lori A.Coburn,James C.Slaughter,RupeshChaturvedi,David A.Schwartz,Keith T.Wilson.Increased serum levels of L‐arginine in ulcerative colitis and correlation with disease severity[J]. Inflamm Bowel Dis . 2009 (1)
  • 8J.L. Mendoza,M.T. Abreu.Biological markers in inflammatory bowel disease: Practical consideration for clinicians[J]. Gastroenterologie Clinique et Biologique . 2009
  • 9Krithika Balasubramanian,Sandeep Kumar,Rajeev R. Singh,Uma Sharma,Vineet Ahuja,Govind K. Makharia,Naranamangalam R. Jagannathan.Metabolism of the colonic mucosa in patients with inflammatory bowel diseases: an in vitro proton magnetic resonance spectroscopy study[J]. Magnetic Resonance Imaging . 2009 (1)
  • 10Gert Van Assche,Séverine Vermeire,Paul Rutgeerts.Infliximab therapy for patients with inflammatory bowel disease: 10&lt;ce:hsp sp="0.25"/&gt;years on[J]. European Journal of Pharmacology . 2009

共引文献24

同被引文献175

引证文献18

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部